Combined radiosensitization and radioprotection for oral cavity tumors: study with an oral cavity tumor model.
Adjuvant therapy with combined radioprotectors and radiosensitizers has not been extensively examined. We investigated the use of combined S-2-(3-aminopropylamino) ethylphosphorothioic acid (WR-2721), misonidazole (Ro-07-0582) and single dose radiotherapy in treating the EMT 6/Ky tumor implanted in the buccal mucosa of Balb/c mice. Our results demonstrate that single dose irradiation plus WR-2721 or misonidazole prolonged the mean survival time (MST) of EMT 6/Ky bearing Balb/c mice significantly compared to either controls or single dose irradiation plus WR-2721 and misonidazole.
D004999:Amifostine / Q000627:therapeutic use; D000818:Animals; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D008920:Misonidazole / Q000627:therapeutic use; D009062:Mouth Neoplasms / Q000532:radiotherapy*; D009374:Neoplasms, Experimental / Q000532:radiotherapy; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D013997:Time Factors
D011837:Radiation-Protective Agents; D011838:Radiation-Sensitizing Agents; D008920:Misonidazole; D004999:Amifostine